ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results